Charles Baum
Director/Board Member at PMV PHARMACEUTICALS, INC.
Net worth: 188 051 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Gergen | M | 61 | 10 years | |
| Peter Thompson | M | 64 |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | 9 years |
| Kristina Masson | M | 44 | 6 years | |
| Richard Heyman | M | 66 | 4 years | |
| Gary D. Glick | M | - |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | - |
| Peter Blume-Jensen | M | 62 | 6 years | |
| David Mack | M | 62 | 11 years | |
| Kristin Yarema | M | 53 | 1 years | |
| Harry Leonhardt | M | 67 | 4 years | |
| Arnold Levine | M | 84 | 11 years | |
| Steven J. Potts | M | - |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
| Johanna Mylet | F | 37 | 9 years | |
| Douglas Giordano | M | 61 | 5 years | |
| Sandra Ramos-Alves | F | - | - | |
| Laurie Stelzer | F | 56 | 4 years | |
| Andrew Dickinson | M | 54 | 4 years | |
| Carol Gallagher | M | 59 | 2 years | |
| Kirsten Flowers | F | 49 | 5 years | |
| Michael Carulli | M | 74 | 4 years | |
| Michael Wood | M | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
| Sally Susman | F | 62 | 17 years | |
| Luke Corning | M | 41 | 4 years | |
| Deepika Jalota | M | 48 | 5 years | |
| Christina Carlson | F | - | 4 years | |
| Devon J. Shedlock | M | - | - | |
| Kimberly McCutcheon Jablonski | F | - | - | |
| Sarah Thailing | F | - | 4 years | |
| Erick Gamelin | M | 67 | 3 years | |
| Derek DiRocco | M | 43 | 3 years | |
| Loren Wagner | M | - | 3 years | |
| Margaret M. Madden | F | - | 5 years | |
| David Pompliano | M | - |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | 3 years |
| Marcea Lloyd | F | 75 | 5 years | |
| Cynthia Collins | F | 65 | 3 years | |
| Bryan Supran | M | - | 5 years | |
| Suzanne Johnson | F | 66 | 17 years | |
| John Schmid | M | 60 | 6 years | |
| Sharon Shacham | M | 53 | 4 years | |
| Kristin Martin | F | 49 | 5 years | |
| Helen Hobbs | M | 71 | 13 years | |
| Brett Pletcher | M | 56 | 4 years | |
| Timothy J. Smith | M | - | 3 years | |
| Michael Tomsicek | M | 58 | 2 years | |
| Robert Ticktin | M | 62 | - | |
| Jill Carroll | F | 48 |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | - |
| Tim Xiao | M | 37 |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
| Kanad D. Das | M | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
| Matthew Jacobson | M | - |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | 3 years |
| Chuck Baum | M | - |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | - |
| Kevin Koch | M | 63 |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | - |
| Annaliesa Anderson | M | - | 17 years | |
| Jason Rushton | M | 54 |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | - |
| Marc Fellous | M | - | 2 years | |
| Rafael Amado | M | 60 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Charles Grubsztajn | M | - | 7 years | |
| Henry McKinnell | M | 81 | 8 years | |
| Jeffrey Kindler | M | 68 | 8 years | |
| William Steere | M | 87 | 28 years | |
| Rodney Lappe | M | 69 | 15 years | |
| Eric Ostertag | M | 51 | 9 years | |
| Kyle A. Lefkoff | M | 64 | 21 years | |
| David L. Snitman | M | 72 | 17 years | |
| Shalini Sharp | F | 49 | 6 years | |
| Amy Schulman | F | 63 | 6 years | |
| Martin Godbout | M | - | 12 years | |
| Vickie Reed | F | 62 | 9 years | |
| Michael R. Garone | M | 66 | 3 years | |
| Perry Johnston | M | - | - | |
| Andrew Robbins | M | 48 | 7 years | |
| James Christensen | M | 55 | 11 years | |
| Michael Pehl | M | 60 | 2 years | |
| Dennis Ausiello | M | 78 | 13 years | |
| William Ringo | M | 78 | 5 years | |
| Harout Semerjian | M | 52 | - | |
| David Shedlarz | M | 75 | 31 years | |
| Winston Kung | M | 48 | 7 years | |
| R. Carruthers | M | 66 | 17 years | |
| Andrea N. Flynn | M | - | 1 years | |
| Thilo Schroeder | M | 42 | 3 years | |
| Tricia Haugeto | F | - | - | |
| Isan Chen | M | 61 | 14 years | |
| Aaron Davis | M | 45 | 6 years | |
| David Meek | M | 59 | 2 years | |
| Daniel Faga | M | 44 | 1 years | |
| John Moore | M | 59 | 15 years | |
| Nicholas A. Saccomano | M | 65 | 30 years | |
| Neil Reisman | M | 62 | 1 years | |
| Gwen A. Fyfe | M | 72 | 7 years | |
| John Orwin | M | 59 | 7 years | |
| Gil van Lunsen | M | 81 | 17 years | |
| David Hirsch | M | 53 | 4 years | |
| Craig Johnson | M | 62 | 11 years | |
| Julie Cherrington | M | 66 | 5 years | |
| Peter Corr | M | 76 | 6 years | |
| Freda Lewis-Hall | M | 69 | 11 years | |
| Michael R. Jirousek | M | 65 | 5 years | |
| Barbara Duncan | F | 59 | 1 years | |
| Faheem Hasnain | M | 65 | 5 years | |
| Scott Canute | M | 63 | 3 years | |
| Alexandra Kropotova | M | 51 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 94 | 94.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Charles Baum
- Personal Network
